CBA.B6-Tnfrsf1a^tm1Blt Tg(CD2-TNF/HBB)211Gkl/Flmg

Status	Available to order
EMMA ID	EM:11021
International strain name	CBA.B6-Tnfrsf1a^tm1Blt Tg(CD2-TNF/HBB)211Gkl/Flmg
Alternative name	CBA.B6-Tnfrsf1a Tg(CD2-TNF/HBB)211Gkl/Flmg
Strain type	Targeted Mutant Strains : Knock-out
Allele/Transgene symbol	Tnfrsf1a^tm1Blt, Tg(CD2-TNF/HBB)211Gkl
Gene/Transgene symbol	Tnfrsf1a, Tg(CD2-TNF/HBB)211Gkl

Information from provider

Provider	George Kollias
Provider affiliation	B.S.R.C.
Genetic information	The transgene comprises the T cell specific human CD2 gene locus control region (LCR) linked to the entire coding region of the human TNF gene with polyadenylation signal and flanking sequences replaced by those of the human hemoglobin beta (HBB) gene. This modification does not interfere with correct translation.
Phenotypic information	Homozygous: embryonic lethality Heterozygous: Lethal wasting syndrome and lymphoid abnormalities. 80-100% mortality occurs within 71-127 days. Affected mice become hunched and unhealthy in appearance typically between 2 and 4 weeks of age. They demonstrate poor growth rates and subsequently severe weight loss. Line is maintained in TNFR1+/- background so that pathology is attenuated.
References	Wasting, ischemia, and lymphoid abnormalities in mice expressing T cell-targeted human tumor necrosis factor transgenes.;Probert L, Keffer J, Corbella P, Cazlaris H, Patsavoudi E, Stephens S, Kaslaris E, Kioussis D, Kollias G, ;1993;Journal of immunology (Baltimore, Md. : 1950);151;1894-906; 8345187
Homozygous fertile	no
Homozygous viable	no
Homozygous matings required	no
Immunocompromised	no

Information from EMMA

Archiving centre	B.S.R.C. Alexander Fleming, Vari, Greece
Animals used for archiving	heterozygous CBA x C57BL/6, wild-type (CBA x C57BL/6)F1
Stage of embryos	Morula

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

Tumor necrosis factor receptor 1 associated periodic syndrome / Orphanet_32960

IMPC phenotypes (gene matching)

abnormal skin morphology / IMPC
increased large unstained cell number / IMPC
increased grip strength / IMPC
increased basophil cell number / IMPC
increased neutrophil cell number / IMPC
increased eosinophil cell number / IMPC
increased NK cell number / IMPC
abnormal cholesterol homeostasis / IMPC
decreased circulating calcium level / IMPC
increased lymphocyte cell number / IMPC
increased effector memory CD8-positive, alpha-beta T cell number / IMPC
increased circulating aspartate transaminase level / IMPC
enlarged heart / IMPC
increased leukocyte cell number / IMPC
decreased monocyte cell number / IMPC
abnormal heart morphology / IMPC
decreased neutrophil cell number / IMPC

MGI phenotypes (allele matching)

abnormal response/metabolism to endogenous compounds / MGI
decreased circulating interleukin-6 level / MGI
decreased sensitivity to induced morbidity/mortality / MGI
decreased physiological sensitivity to xenobiotic / MGI
decreased sensitivity to xenobiotic induced morbidity/mortality / MGI
abnormal sleep pattern / MGI
impaired central nervous system regeneration / MGI
increased sensitivity to induced cell death / MGI
increased susceptibility to bacterial infection induced morbidity/mortality / MGI
impaired humoral immune response / MGI
decreased susceptibility to bacterial infection / MGI
decreased circulating alanine transaminase level / MGI
abnormal Peyer's patch morphology / MGI
abnormal immune system physiology / MGI
abnormal lymph node B cell domain morphology / MGI
abnormal Peyer's patch follicle morphology / MGI
increased susceptibility to bacterial infection / MGI
decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
increased susceptibility to parasitic infection / MGI
increased susceptibility to type I hypersensitivity reaction / MGI
decreased Peyer's patch number / MGI
absent follicular dendritic cells / MGI
decreased IgG1 level / MGI
decreased interleukin-6 secretion / MGI

MGI phenotypes (gene matching)

increased bone mineral density / MGI
abnormal Peyer's patch morphology / MGI
abnormal sleep pattern / MGI
abnormal immune system physiology / MGI
decreased IgG level / MGI
liver inflammation / MGI
lung inflammation / MGI
decreased inflammatory response / MGI
increased skin papilloma incidence / MGI
decreased tumor incidence / MGI
abnormal respiratory mechanics / MGI
abnormal airway responsiveness / MGI
abnormal lymph node B cell domain morphology / MGI
abnormal spleen germinal center morphology / MGI
abnormal Peyer's patch follicle morphology / MGI
decreased susceptibility to bacterial infection / MGI
increased susceptibility to bacterial infection / MGI
abnormal macrophage physiology / MGI
granulomatous inflammation / MGI
impaired skin barrier function / MGI
abnormal glutamate-mediated receptor currents / MGI
decreased circulating alanine transaminase level / MGI
abnormal cytokine secretion / MGI
no phenotypic analysis / MGI
abnormal nervous system physiology / MGI
abnormal response/metabolism to endogenous compounds / MGI
increased susceptibility to experimental autoimmune encephalomyelitis / MGI
decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
decreased susceptibility to autoimmune diabetes / MGI
increased susceptibility to parasitic infection / MGI
increased susceptibility to type I hypersensitivity reaction / MGI
decreased Peyer's patch number / MGI
abnormal follicular dendritic cell morphology / MGI
absent follicular dendritic cells / MGI
decreased IgG1 level / MGI
increased circulating tumor necrosis factor level / MGI
decreased circulating interleukin-6 level / MGI
decreased circulating interleukin-1 beta level / MGI
increased interleukin-6 secretion / MGI
decreased interleukin-6 secretion / MGI
abnormal chemokine secretion / MGI
decreased susceptibility to endotoxin shock / MGI
increased susceptibility to endotoxin shock / MGI
decreased physiological sensitivity to xenobiotic / MGI
increased sensitivity to induced cell death / MGI
increased sensitivity to induced morbidity/mortality / MGI
decreased sensitivity to induced morbidity/mortality / MGI
decreased sensitivity to xenobiotic induced morbidity/mortality / MGI
increased susceptibility to bacterial infection induced morbidity/mortality / MGI
abnormal neuron proliferation / MGI
abnormal oval cell physiology / MGI
tumor regression / MGI
impaired adaptive thermogenesis / MGI
decreased susceptibility to dopaminergic neuron neurotoxicity / MGI
decreased microglial cell number / MGI
impaired humoral immune response / MGI
impaired central nervous system regeneration / MGI

Literature references

Wasting, ischemia, and lymphoid abnormalities in mice expressing T cell-targeted human tumor necrosis factor transgenes.;Probert L, Keffer J, Corbella P, Cazlaris H, Patsavoudi E, Stephens S, Kaslaris E, Kioussis D, Kollias G, ;1993;Journal of immunology (Baltimore, Md. : 1950);151;1894-906; 8345187

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740^*
Rederivation of mice from frozen stock, delivery time available upon request . €3880^*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.

CBA.B6-Tnfrsf1atm1Blt Tg(CD2-TNF/HBB)211Gkl/Flmg